Hematologic Malignancy
Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
CI-CAN-00005967PTCLExplore in graph →
Hematologic172 active trials13 approved drugs9 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00005967PTCLExplore in graph →
Clinical trials
786 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (129)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01273766 | Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies | completed | Phase 2 | 16 | Wake Forest University Health SciencesOTHER | 1 | Sep 7, 2018 | clinicaltrials |
| NCT01686165 | Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL | completed | Phase 2 | 5 | University of ArizonaOTHER | 1 | Aug 28, 2018 | clinicaltrials |
| NCT00136565 | Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma | completed | Phase 2 | 60 | Lymphoma Study AssociationOTHER | 2 | Aug 23, 2018 | clinicaltrials |
| NCT01724177 | A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma | completed | Phase 2 | 26 | CelgeneINDUSTRY | 1 | May 29, 2018 | clinicaltrials |
| NCT00961220 | O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma | completed | Phase 1 / Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | May 22, 2018 | clinicaltrials |
| NCT02825147 | Pegaspargase and Methotrexate Based Regimens for Newly Diagnosed Extranodal NK/T Cell Lymphoma | completed | Phase 2 | 40 | Ruijin HospitalOTHER | 1 | Nov 14, 2017 | clinicaltrials |
| NCT02013362 | Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma | completed | Phase 1 / Phase 2 | 25 | Mundipharma K.K.INDUSTRY | 1 | Nov 9, 2017 | clinicaltrials |
| NCT00073918 | Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 2 | 111 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 18, 2017 | clinicaltrials |
| NCT02276248 | Radiotherapy Combined With GDP Chemotherapy in Stage I/II Extranodal Natural Killer/T-cell Lymphoma | completed | Phase 2 | 40 | Chinese Academy of Medical SciencesOTHER | 1 | Aug 16, 2017 | clinicaltrials |
| NCT00072514 | Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies | completed | Phase 2 | 55 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 29, 2017 | clinicaltrials |
| NCT00118352 | Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 12 | Fred Hutchinson Cancer CenterOTHER | 2 | May 30, 2017 | clinicaltrials |
| NCT00601718 | Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 29 | University of WashingtonOTHER | 1 | May 25, 2017 | clinicaltrials |
| NCT01110135 | Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma | completed | Phase 2 | 43 | University of WashingtonOTHER | 1 | May 24, 2017 | clinicaltrials |
| NCT00795769 | Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant | completed | Phase 2 | 49 | Fred Hutchinson Cancer CenterOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT01427881 | Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies | completed | Phase 2 | 43 | Fred Hutchinson Cancer CenterOTHER | 1 | May 19, 2017 | clinicaltrials |
| NCT00049504 | Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer | completed | Phase 2 | 53 | Fred Hutchinson Cancer CenterOTHER | 1 | May 17, 2017 | clinicaltrials |
| NCT00007345 | Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma | completed | Phase 2 | 131 | National Cancer Institute (NCI)NIH | 2 | May 16, 2017 | clinicaltrials |
| NCT00091559 | Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001) | completed | Phase 2 | 74 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 5, 2017 | clinicaltrials |
| NCT01396070 | Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level | completed | Phase 2 | 36 | Youn KimOTHER | 1 | Apr 5, 2017 | clinicaltrials |
| NCT01173887 | Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15 | completed | Phase 2 | 44 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Mar 30, 2017 | clinicaltrials |
| NCT00920790 | Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma | completed | Phase 2 | 28 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Mar 29, 2017 | clinicaltrials |
| NCT01000285 | EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma(ATLL) | completed | Phase 1 / Phase 2 | 18 | Washington University School of MedicineOTHER | 1 | Mar 28, 2017 | clinicaltrials |
| NCT00611208 | A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL) | completed | Phase 2 | 32 | Virogen Biotechnology Inc.INDUSTRY | 1 | Nov 29, 2016 | clinicaltrials |
| NCT01274533 | Lenalidomide in HTLV-1 Adult T-Cell Leukemia | completed | Phase 2 | 4 | Columbia UniversityOTHER | 1 | May 23, 2016 | clinicaltrials |
| NCT01466881 | Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma | completed | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 2 | Mar 10, 2016 | clinicaltrials |
| NCT00178841 | Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL | completed | Phase 2 | 4 | Vanderbilt UniversityOTHER | 1 | Feb 17, 2016 | clinicaltrials |
| NCT00131937 | Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma | completed | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Sep 3, 2015 | clinicaltrials |
| NCT00431912 | A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma | completed | Phase 2 | 25 | Valerio TherapeuticsINDUSTRY | 4 | Jul 8, 2015 | clinicaltrials |
| NCT00453427 | Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas(ACCAPELA) | completed | Phase 1 / Phase 2 | 20 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Jun 3, 2015 | clinicaltrials |
| NCT00003210 | Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease | completed | Phase 2 | 105 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT00099593 | Immunization Against Tumor Cells in Sezary Syndrome | completed | Phase 2 | 17 | University of PittsburghOTHER | 1 | Mar 25, 2015 | clinicaltrials |
| NCT01198665 | RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas(RADCHOP) | completed | Phase 1 / Phase 2 | 46 | Samsung Medical CenterOTHER | 1 | Mar 3, 2015 | clinicaltrials |
| NCT01238159 | Concomitant Chemo-radiotherapy Followed by MIDLE Chemotherapy in Stage I/II Extranodal NK/T-cell Lymphoma | completed | Phase 2 | 30 | Samsung Medical CenterOTHER | 1 | Mar 3, 2015 | clinicaltrials |
| NCT00337987 | A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma | completed | Phase 2 | 49 | Yale UniversityOTHER | 1 | Feb 27, 2015 | clinicaltrials |
| NCT00079755 | Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma | completed | Phase 2 | 80 | Seagen Inc.INDUSTRY | 1 | Dec 18, 2014 | clinicaltrials |
| NCT00185965 | CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas | completed | Phase 1 / Phase 2 | 30 | Ronald LevyOTHER | 1 | Aug 1, 2014 | clinicaltrials |
| NCT00901147 | Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma | completed | Phase 2 | 25 | Singapore General HospitalOTHER | 3 | Jun 27, 2014 | clinicaltrials |
| NCT00117988 | 17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma | completed | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT00058019 | Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma | completed | Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT01280526 | A Study of Escalating Doses of Romidepsin in Association With CHOP in the Treatment of Peripheral T-Cell Lymphomas(Ro-CHOP) | completed | Phase 1 / Phase 2 | 37 | The Lymphoma Academic Research OrganisationOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT01806337 | CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma | completed | Phase 2 | 41 | University of GöttingenOTHER | 0 | Mar 7, 2013 | clinicaltrials |
| NCT00278382 | Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma | completed | Phase 2 | 33 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT00016094 | S0108 Bevacizumab in Treating Patients With Non-Hodgkin's Lymphoma | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 29, 2013 | clinicaltrials |
| NCT00006473 | Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 2 | 72 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00005080 | 506U78 in Treating Patients With Lymphoma | completed | Phase 2 | 74 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00061048 | Campath-1H for Treating Adult T-Cell Leukemia/Lymphoma | completed | Phase 2 | 29 | National Cancer Institute (NCI)NIH | 1 | Oct 31, 2012 | clinicaltrials |
| NCT00168064 | Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides | completed | Phase 2 | 260 | Yaupon TherapeuticsINDUSTRY | 1 | Oct 31, 2012 | clinicaltrials |
| NCT00535470 | An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides | completed | Phase 2 | 100 | Yaupon TherapeuticsINDUSTRY | 1 | Aug 9, 2012 | clinicaltrials |
| NCT00930605 | The Effectiveness of Alemtuzumab Given in Combination With CHOP and ESHAP in Patients Newly Diagnosed With Peripheral T-Cell Lymphoma (PTCL)(C+CHOP/ESHAP) | completed | Phase 2 | 16 | King Chulalongkorn Memorial HospitalOTHER | 1 | Oct 6, 2011 | clinicaltrials |
| NCT00791947 | A Nordic Phase II Study of PTCL Based on Dose-intensive Induction and High-dose Consolidation With ASCT | completed | Phase 2 | 166 | University of AarhusOTHER | 3 | Sep 8, 2011 | clinicaltrials |
Data updated 23 days agoSource updated Sep 7, 2018source: clinicaltrials